---
title: Improvement in Baroreflex Sensitivity in OSAS
nct_id: NCT00284037
overall_status: UNKNOWN
phase: NA
sponsor: Nagoya University
study_type: INTERVENTIONAL
primary_condition: Obstructive Sleep Apnea Syndrome
countries: Japan
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT00284037.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT00284037"
ct_last_update_post_date: 2006-01-31
last_seen_at: "2026-05-12T07:12:21.885Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Improvement in Baroreflex Sensitivity in OSAS

**NCT ID:** [NCT00284037](https://clinicaltrials.gov/study/NCT00284037)

## Key Facts

- **Status:** UNKNOWN
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Lead Sponsor:** Nagoya University
- **Conditions:** Obstructive Sleep Apnea Syndrome
- **CT.gov Last Update:** 2006-01-31

## Brief Summary

Individuals with obstructive sleep apnea syndrome (OSAS) are at high risk for cardiovascular morbidity and mortality. The effect of long-term nocturnal therapy with continuous positive airway pressure (CPAP) on daytime baroreflex sensitivity (BRS), a predictor of cardiac death, was investigated in OSAS patients.

## Eligibility

- **Minimum age:** 20 Years
- **Maximum age:** 70 Years
- **Sex:** ALL

```
Inclusion Criteria:

* obstructive sleep apnea syndrome

Exclusion Criteria:

* diabetes mellitus, chronic obstructive lung disease, coronary or valvular heart disease, congestive heart failure, renal failure, or endocrine dysfunction. Moreover, none of them were taking b-blockers, vasodilators, or inotropic agents at the time of enrollment in the study.
```

## Interventions

- **continuous positive airway pressure therapy** (DEVICE)

## Locations (1)

- Nagoya University of Health Sciences, Nagoya, Japan — _RECRUITING_

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.nagoya university of health sciences|nagoya||japan` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT00284037.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT00284037*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*